Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, causing selective degradation of transcription factors Ikaros and Aiolos. This triggers immunomodulation, reduces angiogenesis, and directly inhibits the growth of malignant plasma and lymphoid cells, contributing to its antineoplastic effect.

The specific dose of Lenalidomid Zentiva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved labeling and clinical guidelines to set an appropriate regimen.

Lenalidomid Zentiva is classified as Pregnancy Category X because it is known to cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is not recommended while using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide is a more potent analogue of thalidomide with enhanced immunomodulatory activity and a generally more favorable safety profile. It exhibits stronger anti‑angiogenic effects and lower incidence of peripheral neuropathy, though both drugs share risks such as teratogenicity and thromboembolic events.

Lenalidomid Zentiva should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lenalidomid Zentiva is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding; venous thromboembolism; secondary primary malignancies; and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events.

Lenalidomid Zentiva is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose‑adjusted. It should also be avoided in patients with uncontrolled active infections or those unable to adhere to strict pregnancy‑prevention programs.